Business
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW,
About this update from Briacell Therapeutics Corp
[{"type":"image","alt":"BriaCell Therapeutics Corp.","displaySize":"","headline":null,"caption":"BriaCell Therapeutics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VF.3uZP0Y9S.3O0ulWOxbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7","width":300,"height":263}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancer","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Expands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical need","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Principal Investigator: Dr. William Oh, MD, Yale Cancer Center","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":370,"olType":false},{"type":"text","content":"PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cancer Institute (NCI), the United States federal government’s principal agency for cancer research and training, has awarded the Company a research grant of $2,054,651 to advance Bria-PROS+, BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer.","length":607,"tagName":"p"},{"type":"text","content":"The non-dilutive grant, titled “Phase 1/2a clinical trial to investigate Bria-PROS+™ in patients with metastatic prostate cancer”, will be used to complete manufacturing of Bria-PROS+ and to fund the upcoming Phase 1/2a study in patients with advanced prostate cancer.","length":273,"tagName":"p"},{"type":"text","content":"“Despite recent advances in the management of metastatic hormone-sensitive prostate cancer, most patients will progress with significant pain and suffering and limited treatmen...